Free tool
FAERS Monitor: Enoby
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 761439 or its brand name (Enoby, Denosumab-Qbde). Reports on generic versions are filed under their own applications.
Reports
3
Serious
0
0% of reports
Hospitalization
0
Death reported
0
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- accidental underdose1
- pain in extremity1
- product dose omission issue1
- rash1
- swollen tongue1
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2026 | 3 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,156 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| accidental underdose | 1 | 487.1 | 98.3 | 121 |
| swollen tongue | 1 | 224.5 | 45.3 | 55 |
| product dose omission issue | 1 | 23.8 | 4.8 | 5 |
| pain in extremity | 1 | 23.8 | 4.8 | 5 |
| rash | 1 | 16.1 | 3.2 | 3 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.